Mat Rasid, Siti Norain and Khatib, Alfi and Nando, Dendi Noventri and Ahmad Mizher, Hussam Abdeljabar and Mohd Nasir, Mohd Hamzah and Arzmi, Mohd Hafiz (2025) In silico discovery of α-glucosidase inhibitors from Mitragyna speciosa for antidiabetic therapy. In: 1st International Biomedical Conference 2025, 3-4 Sep 2025, Kuantan, Malaysia.
|
PDF (Abstract)
- Published Version
Download (4MB) | Preview |
Abstract
INTRODUCTION: Mitragyna speciosa (kratom) is a medicinal plant known for its richness in phytochemicals with potential antidiabetic activity. α-glucosidase is an enzyme that plays a key role in carbohydrate hydrolysis. The inhibition of α-glucosidase activity represents a validated therapeutic approach to manage postprandial hyperglycaemia in type 2 diabetes. This study investigates the potential of M. speciosa leaf extract as an α-glucosidase inhibitor. OBJECTIVE(S): To identify bioactive compounds in M. speciosa ethanolic leaf extract that inhibit α-glucosidase and to evaluate their interaction with the enzyme through in silico molecular docking. MATERIALS & METHODS: Phytochemical profiling of the 95% ethanolic extract of M. speciosa leaf was performed using LC-MS QTOF. In vitro α-glucosidase inhibition assay was conducted to determine the IC₅₀ value of the extract. Selected compounds were subjected to molecular docking analysis using AutoDock software against α-glucosidase enzyme (PDB ID: 3A4A), and key binding interactions were analysed. RESULTS: A total of 16 putative bioactive compounds were identified from the extract. The extract exhibited α-glucosidase inhibitory activity with an IC₅₀ of 21.64 µg/mL. In the molecular docking analysis, Rhyncophylline showed strong binding to α-glucosidase (ΔG = -8.8 kcal/mol), comparable to standard inhibitors. Its interaction with ASP352, a known catalytic residue, suggests that Rhyncophylline may act as a potential α-glucosidase inhibitor. CONCLUSION: The ethanolic leaf extract of M. speciosa exhibits α-glucosidase inhibitory activity. Rhyncophylline, identified via in silico docking, is a promising lead compound for future antidiabetic drug development.
| Item Type: | Proceeding Paper (Poster) |
|---|---|
| Uncontrolled Keywords: | Mitragyna speciosa, α-Glucosidase, Molecular Docking, Rhyncophylline |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button): | Kulliyyah of Dentistry Kulliyyah of Dentistry > Department of Fundamental Dental and Medical Sciences Kulliyyah of Pharmacy Kulliyyah of Pharmacy > Department of Basic Medical Sciences Kulliyyah of Pharmacy > Department of Pharmaceutical Chemistry Kulliyyah of Science Kulliyyah of Science > Department of Biotechnology Kulliyyah of Medicine Kulliyyah of Medicine > Department of Basic Medical |
| Depositing User: | Dr. Siti Norain Mat Rasid |
| Date Deposited: | 16 Dec 2025 15:06 |
| Last Modified: | 16 Dec 2025 15:06 |
| Queue Number: | 2025-12-Q989 |
| URI: | http://irep.iium.edu.my/id/eprint/125079 |
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics